Your Health, We Care
Release date: 2024-08-28 16:52:41 Recommended: 166
Stiripentol is a drug that reduces seizures by modulating GABA receptors, especially for patients with Dravet syndrome. It has demonstrated significant efficacy in clinical trials, bringing important therapeutic breakthroughs to patients at high risk of status epilepticus.
Stiripentol has corresponding drug indications, and patients should learn more about it.
Stiripentol is mainly used for the treatment of seizures associated with Dravet syndrome (DS) and is suitable for patients over 6 months of age who are taking clobazam and weigh 7 kg or more. There is no evidence that stirifanol can be used as a monotherapy for Dravet syndrome.
Knowing the indications of a drug can help patients make better choices about their medications, and patients should also be aware of the potential for common side effects of medications.
Patients should pay attention to common adverse reactions, and intervene and treat them in a timely manner.
Hypotonia is manifested by muscles becoming too relaxed, and patients may find themselves having more difficulty performing fine movements or maintaining posture. This symptom can lead to decreased exercise capacity and postural instability.
Nausea is a feeling of upset in the stomach, usually accompanied by a feeling of wanting to vomit. This discomfort may interfere with eating, may lead to vomiting, and further affect the patient's nutritional intake and daily activities.
Patients should learn more about other related possible side effects and precautions for medication, and seek medical attention and professional help if symptoms occur.
Understanding the precautions for the use of medications is essential for the treatment of patients.
Stiripentol in oral suspension contains phenylalanine, which is harmful to patients with phenylketonuria (PKU). Total phenylalanine intake should be considered before use. The capsule form does not contain phenylalanine.
Anti-epileptic drugs may increase the risk of suicidal thoughts and behavior. Doctors need to balance the risk of suicide with the risk of the disease itself. Patients and family members should be alert to depressive symptoms and behavioral changes, and report them in a timely manner.
Patients should be aware of whether their reactions are related to the use of drugs and actively report symptoms to their doctor.
[Warm tips] Patients should maintain a positive and optimistic attitude during the treatment period, and actively cooperate with the doctor to take medication and treatment, so as to overcome the disease and achieve the expected results.
